We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Company To Promote and Commercialize bioMerieux Range in Japan

By HospiMedica staff writers
Posted on 22 Jan 2008
Sysmex Corp. More...
(Kobe, Japan; www.sysmex.com) and bioMerieux (Marcy l'Etoile, France; www.biomerieux.com) have signed an agreement to form a new company called Sysmex bioMerieux, Ltd. The company will promote and commercialize the entire bioMerieux product range in Japan.

bioMerieux has been operating in the Japanese clinical diagnostics and industrial testing market through bioMerieux Japan, Ltd., a fully owned subsidiary. The joint venture (JV) will manage the regulatory filing and marketing activities of bioMerieux product ranges in Japan. The sales and customer service activities will be contracted out from the JV to Sysmex.

Sysmex and bioMerieux have been developing their global partnership since July 2007, when bioMerieux became a global partner to distribute Sysmex's highly standardized and automated UF-1000i urine sediment analyzer to their extensive clinical microbiology customer base.

bioMérieux provides diagnostic products (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

Sysmex performs clinical laboratory testing of blood, urine, and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems. The company, which specialized in hematology, has expanded to offer a comprehensive range of diagnostics products and solutions in the diagnostics field including coagulation, biochemistry, immunochemistry, urinalysis, and other disciplines.

The market volume of microbiology testing in Japan is estimated at approximately US$280 million per year and is regarded as a strategically important market, the second largest in size worldwide.


Related Links:
Sysmex Corporation
bioMerieux

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.